These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 25072544

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.
    Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R.
    Int J Cardiol; 2013 Mar 10; 163(3):320-325. PubMed ID: 23073279
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R.
    Rev Port Cardiol; 2000 Nov 10; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [Abstract] [Full Text] [Related]

  • 26. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.
    Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD.
    Biochim Biophys Acta; 2011 Jul 10; 1813(7):1333-50. PubMed ID: 21256164
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov 10; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 32. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
    Lopaschuk GD.
    Am J Cardiol; 1998 Sep 03; 82(5A):14K-17K. PubMed ID: 9737481
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.
    Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, Lopaschuk GD.
    Circ Heart Fail; 2013 Sep 01; 6(5):1039-48. PubMed ID: 23861485
    [Abstract] [Full Text] [Related]

  • 36. Metabolic therapy for heart failure.
    Essop MF, Opie LH.
    Eur Heart J; 2004 Oct 01; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Metabolic therapy for the diabetic patients with ischaemic heart disease.
    Rosano GM, Vitale C, Volterrani M, Fini M.
    Coron Artery Dis; 2005 Nov 01; 16 Suppl 1():S17-21. PubMed ID: 16340399
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.